05909
U.S. PTO

UTILITY	Attorney Docket No.: 14014.0266U3				
PATENT APPLICATION	First Inve	entor:	!	MATSUI, Toshimits	su
TRANSMITTAL	Title: Antibodies for the Alpha Platel			for the Alpha Plate	elet-Derived Growth Factor Receptor
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No.: EL 992019138US				
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility application contents	ADDRESS TO: Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			or Patents	
Specification Total Pages 39 (Includes description, claims, and abstract	-	6. 🗆		D-ROM or CD-R ir omputer Program (n duplicate, large tables or (Appendix)
				ACCOMPANYING	APPLICATION PARTS:
2. Drawings [Total Sheets 2]	7]	7.		Copy of Assignmer	nt
3. Oath or Declaration [Total Pages 9]		8.	_	, ,	atement (when there is an assignee)
				Power of Attorney	5 (7 5 1)
a. ☐ Newly executed (original or copy) 10. ☐ English Translati b. ☒ Copy from a prior application (37 CFR 1.63(d))			Document (if applicable)		
(for continuation/divisional with Box 20B		11.	□ I	Information Disclos	sure Statement/PTO-1449
completed)	-		Ċ	Copies of IDS Cita	-
4. Application Data Sheet. See 37 CFR 1			_	Preliminary Amend	
[Total Pages		13.		Certified Copy of P priority is claimed)	riority Document(s) (if foreign
5. ⊠ Nucleotide and/or Amino Acid Sequenc Submission (if applicable, all necessary)	e	14.			quest under 35 USC 122(b)(2)(B)(i) PTO/SB/35 or equivalent).
a. Computer Readable Form (CRF)		15.		•	eat Reply Requiring Extension of
OR M Statement under 37 CEP 1 821(a) (see 5	Roy 21	13.			ting Petition for Extension of Time
Statement under 37 CFR 1.821(e) (see Box 21 for statement)		16.	× I	Return Receipt Pos	stcard (MPEP 503)
b. Specification Sequence Listing on:		17.		Other:	
i. CD-ROM or CD-R (2 copies); or					
ii. ⊠ paper [9 Pages] c. ⊠ The contents of the computer readable fo	orm of				
the sequence listing and the sequence lis	sting in				
the specification of the application are the	e same.				
18. The FILING FEE is calculated as follows: (Cla	ims as file	d, less a	any o	daims cancelled by	y Amendment)
Claims Number Filed		ber Ext		Rate	\$770.00 (Basic Fee)
Total claims [] – 20 =				X \$18.00	\$ 0
Independent claims []-3=				X \$86.00	\$0
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + 290.00		\$0			
TOTAL OF ABOVE CALCULATIONS =		\$770.00			
Applicant claims small entity status. See 37 CFR 1.27. Fees are reduced by 1/2		\$			
TOTAL FILING FEE =		\$770.00			
19. Payment: ☐ A check in the amount of \$ is enclosed. ☐ Credit Card Payment Form PTO-2038 Authorizing Payment in the amount of \$770.00 is enclosed. ☐ The Commissioner is hereby authorized to charge any additional amount due or credit any overpayment to Deposit Account No. 14-0629.					



20A.		This application is an original application (not a continuation, divisional or continuation-in-part).		
208.	⊠	This application is a continuation-in-part / \(\) continuation / divisional of prior Application No. 09/769,987. The prior application was assigned to Examiner D. Crouch , Group Art Unit 1632. The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference.		
	\boxtimes	This application is a continuation or divisional application (not a continuation-in-part) that:		
		• •	an all the inventors named in the prior application; and	
		(ii) contains no matter that would have been new matter in the prior application; and (iii) a copy of the executed oath or declaration in the prior application, showing the signature or an		
		indication thereon that it was signed:	in the phot application, showing the signature of an	
		is enclosed.		
		will follow.	and an analysis of a series fled by	
		This application is a continuation or divisional application (not a continuation-in-part) that is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. §1.63(d)(2), the Commissioner is requested to delete the name(s) of the following person who are not inventors of the invention being claimed in this application:		
	0	This application is a continuation-in-part, continuationamed in the prior application. A newly executed of is enclosed. will follow.	on or divisional application naming an inventor not path or declaration:	
21.		A sequence listing in computer readable form in compliance with 37 C.F.R. §§ 1.821-1.825 was submitted on 10/09/2001 in prior Application No. 09/769,987, filed May 17, 2001. Pursuant to 37 C.F.R. § 1.821(e), applicant hereby requests that the computer readable form of the sequence listing submitted in the above-referenced prior application be used as the computer readable form of the sequence listing for the new application. The paper or compact disk copy of the Sequence Listing in the new application is identical to the computer readable copy filed in the prior application.		
22.		This application claims foreign priority benefits und application(s) listed below, or under 35 USC 365(a Application No Country:	or 365(b) of any PCT application listed below.	
23. Address all correspondence to the address associated with: CUSTOMER NO. 36339				
Name o	of Attorney	/Agent: Gwendolyn D. Spratt	Registration No.: 36,016	
		weddyn 8. Spratt	Date: 11-3-03	
Certificate of Express Mailing Under 37 C.F.R. § 1.10				
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL 992019138US, in an envelope addressed to: Mail Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.				
Jeffrey	My Teems	S Jeens	11-03-03 Date	
Lacine	100110		Date	

ATTORNEY DOCKET NO. 14014.0266U3 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
MATSUI, Toshimitsu) Art Unit: Unassigned
Application No. Unassigned (Continuation filed from App. No. 09/769,987) Examiner: Unassigned)
Filing Date: Concurrently) Confirmation No. Unassigned
For: ANTIBODIES FOR THE ALPHA PLATELET-DERVIED GROWTH FACTOR RECEPTOR)))

AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME AS INCORPORATING PETITION FOR EXTENSION OF TIME

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer Number 36339

Sir:

Pursuant to 37 C.F.R. §1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time for the appropriate length of time.

ATTORNEY DOCKET NO. 14014.0266U3 Application No. Unassigned

The Commissioner is hereby authorized to charge any additional amount which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Gwendolyn D. Spratt Registration No. 36,016

NEEDLE & ROSENBERG, P.C. Customer Number 36339 (678) 420-9300 (Phone) (678) 429-9301 (Fax)

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10		
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL 992019138 US, in an envelope addressed to: Mail Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.		
John J Lews	//-03-03	
Jerrey Leems O	Date	